Page 99 - Read Online

Page 276 Thomas et al. J Transl Genet Genom 2024;8:249-77 https://dx.doi.org/10.20517/jtgg.2024.15

expressed in tumor-associated fibroblasts. Cancer Res 2005;65:11156-63. DOI PubMed
247. Wen Y, Wang CT, Ma TT, et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival
in a murine colon cancer model. Cancer Sci 2010;101:2325-32. DOI PubMed PMC
248. Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances
antitumor therapy. Mol Ther 2014;22:102-11. DOI PubMed PMC
249. Freedman JD, Duffy MR, Lei-Rossmann J, et al. An oncolytic virus expressing a T-cell engager simultaneously targets cancer and
immunosuppressive stromal cells. Cancer Res 2018;78:6852-65. DOI
250. Chaudary N, Pintilie M, Jelveh S, Lindsay P, Hill RP, Milosevic M. Plerixafor improves primary tumor response and reduces
metastases in cervical cancer treated with radio-chemotherapy. Clin Cancer Res 2017;23:1242-9. DOI PubMed
251. Kim ST, Hong JY, Park SH, et al. First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid
tumor patients. Ther Adv Med Oncol 2020;12:1758835920926796. DOI PubMed PMC
252. Zhang X, Luo H. Effects of thalidomide on growth and VEGF-A expression in SW480 colon cancer cells. Oncol Lett 2018;15:3313-
20. DOI PubMed PMC
253. Pulte ED, Dmytrijuk A, Nie L, et al. FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell
transplant in newly diagnosed multiple myeloma. Oncologist 2018;23:734-9. DOI PubMed PMC
254. Summers J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell
carcinoma. Oncologist 2010;15:104-11. DOI PubMed PMC
255. Singh AD, Parmar S. Ramucirumab (Cyramza): a breakthrough treatment for gastric cancer. P T 2015;40:430-68. PubMed PMC
256. Chiorean EG, Sweeney C, Youssoufian H, et al. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha
(PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2014;73:595-604. DOI
257. Kwon MJ. Matrix metalloproteinases as therapeutic targets in breast cancer. Front Oncol 2022;12:1108695. DOI PubMed PMC
258. Nadal L, Corbellari R, Villa A, et al. Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin
C efficiently target tumors in vivo. MAbs 2020;12:1836713. DOI PubMed PMC
259. Neesse A, Frese KK, Bapiro TE, et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing
drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci USA 2013;110:12325-30. DOI PubMed PMC
260. Ke FY, Chen WY, Lin MC, Hwang YC, Kuo KT, Wu HC. Novel monoclonal antibody against integrin α3 shows therapeutic
potential for ovarian cancer. Cancer Sci 2020;111:3478-92. DOI PubMed PMC
261. Sun Y, Zhao C, Ye Y, et al. High expression of fibronectin 1 indicates poor prognosis in gastric cancer. Oncol Lett 2020;19:93-102.
DOI PubMed PMC
262. Streel G, Lucas S. Targeting immunosuppression by TGF-β1 for cancer immunotherapy. Biochem Pharmacol 2021;192:114697.
DOI PubMed PMC
263. Ma C, Xi S, Sun H, Zhang M, Pei Y. Identifying the oncogenic roles of FAP in human cancers based on systematic analysis. Aging
2023;15:7056-83. DOI PubMed PMC
264. Martori C, Sanchez-Moral L, Paul T, et al. Macrophages as a therapeutic target in metastatic prostate cancer: a way to overcome
immunotherapy resistance? Cancers 2022;14:440. DOI PubMed PMC
265. Gordon S, Plüddemann A. The mononuclear phagocytic system. generation of diversity. Front Immunol 2019;10:1893. DOI
PubMed PMC
266. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014;6:13.
DOI PubMed PMC
267. Das A, Sinha M, Datta S, et al. Monocyte and macrophage plasticity in tissue repair and regeneration. Am J Pathol 2015;185:2596-
606. DOI PubMed PMC
268. Gordon S, Plüddemann A. Tissue macrophages: heterogeneity and functions. BMC Biol 2017;15:53. DOI PubMed PMC
269. He MX, Cuoco MS, Crowdis J, et al. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med
2021;27:426-33. DOI PubMed PMC
270. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. Macrophages sequentially change their functional phenotype in
response to changes in microenvironmental influences. J Immunol 2005;175:342-9. DOI PubMed
271. Li XF, Selli C, Zhou HL, et al. Macrophages promote anti-androgen resistance in prostate cancer bone disease. J Exp Med 2023:220.
DOI PubMed PMC
272. Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov
2022;21:799-820. DOI PubMed PMC
273. Abram CL, Lowell CA. The diverse functions of Src family kinases in macrophages. Front Biosci 2008;13:4426-50. DOI PubMed
PMC
274. Loi M, Salvatore G, Sottili M, et al. Tumor-associated macrophages (TAMs) modulate response to HER2-targeted agents in a
humanized mouse model of breast cancer. Clin Transl Oncol 2022;24:1395-402. DOI
275. Watanabe H, Ohashi K, Nishii K, et al. A long-term response to nivolumab in a case of PD-L1-negative lung adenocarcinoma with an
EGFR mutation and surrounding PD-L1-positive tumor-associated macrophages. Intern Med 2019;58:3033-7. DOI PubMed PMC
276. Su S, Lei A, Wang X, et al. Induced CAR-macrophages as a novel therapeutic cell type for cancer immune cell therapies. Cells
2022;11:1652. DOI PubMed PMC
277. Liu M, Liu J, Liang Z, et al. CAR-macrophages and CAR-T cells synergistically kill tumor cells in vitro. Cells 2022;11:3692. DOI
PubMed PMC